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Purpose: To prospectively investigate adverse reactions to bimatoprost in Japanese patients 
with glaucoma or ocular hypertension. We also examined patient attitudes to adverse reactions 
via a questionnaire.
Methods: Fifty-two Japanese patients with glaucoma or ocular hypertension were enrolled. 
Iridial, eyelid, and eyelash photographs were taken before and at 6 months after bimatoprost 
treatment. Increase in eyelid pigmentation, iridial pigmentation, eyelash growth and bristle, and 
vellus hair of the lid was assessed from the photographs. Questionnaires completed by patients 
provided insight into their subjective judgment of adverse reactions.
Results: Increase in eyelash bristle (53.8%), iris pigmentation (50.0%), eyelash growth (46.2%), 
vellus hair of the lid (40.4%), and eyelid pigmentation (7.7%) was evident after bimatoprost 
treatment. The objective and subjective assessments were in agreement in terms of increase in 
eyelash bristle, eyelash growth, and increase in vellus hair of the lid.
Conclusion: Most patients were conscious of these adverse reactions. Before administering 
bimatoprost, sufficient explanation of potential adverse reactions should be provided; after 
initiating treatment, careful observation is required.
Keywords: bimatoprost, adverse reaction, eyelid pigmentation, changes in eyelashes, iris 
pigmentation
Introduction
In Japan, bimatoprost (Lumigan®, Allergan Inc, Irvine, CA) was approved after 
latanoprost, travoprost, and tafluprost as a prost-type prostaglandin analog in 2009. 
Latanoprost, travoprost, and tafluprost selectively interact with a prostaglandin F (PGF) 
receptor to reduce intraocular pressure by increasing uveoscleral outflow. Bimatoprost 
is an endogenous bioactive substance of PGF2α, an analog with a chemical structure 
similar to PGF2α, which selectively interacts with prostaglandin receptors to reduce 
intraocular pressure.1 In a randomized-monocular test, bimatoprost was statistically 
and clinically superior to latanoprost for treatment of open-angle glaucoma or ocular 
hypertension in Japanese patients.2 Bimatoprost also has a greater hypotensive effect 
compared to latanoprost in normal-tension glaucoma,3 chronic glaucoma or ocular 
hypertension,4 a greater hypotensive effect compared to timolol in chronic glaucoma 
or ocular hypertension,5 and an equivalent hypotensive effect to latanoprost and tra-
voprost in open-angle glaucoma and ocular hypertension.6,7
Adverse reactions such as conjunctival injection, changes in eyelashes,   eyelid 
pigmentation, iris pigmentation, and superficial punctate keratitis associated 
with bimatoprost, latanoprost, travoprost, and tafluprost have been reported.2–13 
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However, only a few studies have examined changes in 
eyelashes, eyelid pigmentation, and iris pigmentation after 
bimatoprost treatment in Japanese glaucoma patients.2
In this study, we objectively and subjectively evaluated 
the frequency of adverse effects such as eyelash growth 
and bristle, eyelid pigmentation, increase in vellus hair of 
the lid, and iris pigmentation when prescribing bimato-
prost for 6 months to patients with glaucoma or ocular 
hypertension.
Subjects and methods
Subjects
Fifty-two Japanese patients (22 male, 30 female) aged 
32–81 years (mean, 57.3; standard deviation, 13.1) were 
enrolled in this study. The types of glaucoma present in 
the sample included 47 cases of normal-tension glau-
coma, four of primary open-angle glaucoma, and one of 
ocular   hypertension. At first, we enrolled 70 patients. But 
18 patients discontinued treatment before 6 months due 
to noncompliance or inability to meet schedule (n = 4), 
  hyperemia (n = 6), deepening of the upper eyelid sulcus 
(n = 3), and eyelid pigmentation, eyelash bristle, eye pain, 
headache, and foggy eyesight (n = 1 for each). These 
18 patients were excluded from photograph judgment 
whereas all 52 patients were included in the questionnaire 
of subjective adverse reaction judgment. The standard types 
of each adverse reaction are shown in Figure 1.
This study was approved by the Ethics Committee of 
Inouye Eye Hospital. The subjects were Japanese patients 
with primary open-angle glaucoma or ocular hypertension 
that had not been treated before. The patients received treat-
ment with bimatoprost monotherapy at Inouye Eye Hospital 
from December 2009 to October 2010. All subjects provided 
written informed consent prior to participation in the study. 
For statistical analysis, if both eyes were eligible, the right 
eye was chosen.
Patients were adequately informed about the details of 
the study and adverse reactions regarding eyelash growth 
and bristliness, increase in the amount of vellus hair of the 
lid, eyelid pigmentation, and iris pigmentation that might 
occur when using bimatoprost. Eye drops were administered 
once daily in the evening, and facial (eyelid) cleansing was 
recommended after treatment.
Photography
We photographed the anterior segment before and after 
bimatoprost use for 6 months. Eyes of healthy people (n = 9) 
Before treatment
A
After 6 months of treatment
Figure 1 Adverse reactions to bimatoprost around the eyes (A) Iris pigmentation, 
(B) Increase in vellus hair of the lid, (C) Eyelid pigmentation, (D) Eyelash growth 
and bristliness.
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B
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C
After 6 months of treatment
Before treatment
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After 6 months of treatment
who had no eye disease other than refractive error were also 
photographed and served as controls.
Biomicroscopy was performed using a slit lamp (RS-1000; 
Right Mfg Co, Ltd, Miyagi, Japan) and Nikon D200 digital 
camera (Tokyo, Japan) at a resolution of 10 megapixels. 
Lighting for the photographs was directed at 30° from 
the ipsilateral ear side. The whole iris was photographed 
with diffuse light (10 times, manual flash mode, amount of 
light = 3) and the eyelids were photographed in open and 
closed positions with diffuse light (7.5 times, manual flash 
mode, amount of light = 1). The images were recorded by 
an electronic filing system (VK-2 Server, Kowa, Nagoya, 
Japan), and a dye-sublimation thermal transfer printer 
(CP900D, Mitsubishi, Tokyo, Japan) was used for printing. 
Photography was performed by four skilled operators.
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Questionnaire survey
After 6 months of treatment, we conducted a survey using 
a written questionnaire to evaluate patients’ subjective 
  judgment regarding the treatment. The survey consisted of 
the following questions:
1.  Did your eyelashes grow?
2.  Did your eyelashes become bristly?
3.  Did the vellus (fine, light-colored hair) around your 
eyelids grow?
4.  Did the skin around your eyes become darker?
5.  Did the iris become darker?
6.  Did you notice any other change(s)?
All questions were required to be answered with either 
“Yes” or “No”.
Appearance of adverse reactions
Investigator-masked judgment was individually performed 
by three ophthalmologists who compared pictures obtained 
before and after treatment with bimatoprost, as well as 
controls. They judged the existence or nonexistence of five 
criteria (eyelash growth, eyelash bristle, increase in vellus 
hair of the eyelid, eyelid pigmentation, and iris pigmentation). 
The presence of adverse reactions was defined as agreement 
by at least two of the three ophthalmologists.
Statistics
The primary safety variable was analyzed by Fisher’s exact 
test or Chi-square test. Independent t-tests were used to 
analyze variables between groups and paired t-tests within 
groups. A P value of 0.05 was considered significant.
Results
Appearance of adverse reactions
We compared cases where treatment was discontinued 
within 6 months of administration (18 cases) to cases 
where treatment continued for 6 months (52 cases). Mean 
ages were 63.7 ± 11.4 years in the discontinued group and 
57.3 ± 13.1 years in the continued group, which did not 
represent a significant difference (P = 0.07). Gender in the 
discontinued group (male = 4, female = 14) and the continued 
group (male = 22, female = 30) was not significantly different 
(P = 0.22). Disease type for the discontinued group (normal 
tension glaucoma = 14, primary open-angle glaucoma = 3, 
ocular hypertension = 1) and the continued group (normal 
tension glaucoma = 47, primary open-angle glaucoma = 4, 
ocular hypertension = 1) was not significantly different 
(P = 0.38). Intraocular pressure before administering 
bimatoprost was 17.5 ± 3.5 mmHg in the discontinued group 
and 17.5 ± 3.1 mmHg in the continued group, which did not 
represent a significant difference (P = 0.98).
Forty-two of 52 patients (80.8%) were judged to have had 
adverse reactions to treatment, such as eyelash growth and 
bristle, increase in vellus hair of the lid, eyelid   pigmentation, 
or iris pigmentation (Figure 2). Among these patients, 
45.2% were men and 54.8% women. Their mean age was 
59.6 ± 11.6 years. There was no statistically significant dif-
ference in the incidence of adverse reactions between men 
and women (P = 0.60; Fisher’s exact test). Patients without 
adverse reactions (mean age 47.5 ± 15.1 years) were signifi-
cantly younger than those with adverse reactions (mean age 
59.9 ± 11.8 years) (P = 0.0075; independent t-test). Eyelash 
growth was seen in 24 cases (46.2%), eyelash bristle in 28 
cases (53.8%), increase in vellus hair of the lid in 21 cases 
(40.4%), eyelid pigmentation in four cases (7.7%), and iris 
pigmentation in 26 cases (50.0%).
Self-assessment questionnaire
According to patients’ self-assessment questionnaires, eye-
lashes grew longer in 28 cases (53.8%), eyelashes became 
more bristled in 26 cases (50.0%), vellus hair of the lid 
became thicker in 17 cases (32.7%), and skin around the eyes 
became darker (eyelid pigmentation) in 23 cases (44.2%) 
(Figure 3). There were no differences in the subjective evalua-
tion among these four adverse reactions (P = 0.15; Chi-square 
test). Iris pigmentation was reported in five cases (9.6%), 
which was significantly lower than the other four reported 
adverse reactions (P , 0.0001; Chi-square test).
Comparison of objective and subjective 
judgments
According to the objective judgment, 24 patients had adverse 
reactions of eyelash growth. But among these individuals, 
0%
50.0 50.0
7.7 92.3
59.6 40.4
53.8 46.2
**
53.8 46.2
Appeared Did not appear
Iris pigmentation
Eyelid pigmentation
Increase of vellus hair
of the lid
Eyelash bristle
Eyelash growth
10%20%30%40%50%60%70%80%90% 100%
Figure 2 Objective evaluation.
Note: **P , 0.0001 (chi-square test).
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only 15 answered “yes” to the subjective judgment (Figure 4). 
In only 14 of 28 patients (50.0%) for eyelash bristle, 10 
of 21 (47.6%) for increase in vellus hair, zero of four (0.0%) 
for eyelid pigmentation, and three of 26 (11.5%) for iris 
pigmentation was there agreement between the subjective 
assessment and objective judgment. According to objective 
judgment, 28 patients did not have eyelash growth. But only 
15 answered “no” to the subjective judgment (Figure 4). 
Correspondence between objective and subjective negative 
judgments was as follows: 12 of 24 (50.0%) for eyelash 
bristle, 24 of 31 (77.4%) for increase in vellus hair, 25 of 
48 (52.1%) for eyelid pigmentation, and 24 of 26 (92.3%) 
for iris pigmentation. Positive subjective/objective cor-
respondence (both “yes”) for eyelid pigmentation and iris 
pigmentation was significantly lower than that for eyelash 
growth, eyelash bristle, and increase in vellus hair of the lid 
(P , 0.0001; Chi-square test).
Discussion
To gain approval for bimatoprost use in Japan, 77   Japanese 
patients entered a 12-week clinical trial.2 The rate of 
adverse reactions was 66.2%; these reactions included 
  conjunctival injection (40.3%), eyelash growth (31.2%), 
eyelid   pigmentation (10.4%), pruritus (7.8%), dysesthesia 
of the eye (5.2%), and conjunctival chemosis (5.2%). The 
incidence of these adverse reactions was higher than that 
reported for latanoprost.2
In this study, we found that adverse reactions around the 
eyes such as eyelash growth and bristle, increase in   vellus 
hair of the lid, eyelid pigmentation, and iris pigmentation 
appeared in 80.8% of patients. However in this study, 
18 cases discontinued administration of bimatoprost within 
6 months. One case each of eyelid pigmentation and eyelash 
bristle was included. Moreover, in cases where patients 
discontinued treatment, except for adverse reactions, there 
are possibilities of appearances of adverse reactions around 
the eyes that could not be evaluated in this study. This study 
is an evaluation of administering bimatoprost for 6 months. 
Therefore, there is a possibility that it underevaluated the 
actual appearance of adverse reactions. In this present study, 
extraneous factors between patients who discontinued admin-
istration before 6 months and cases where treatment contin-
ued for 6 months were compared. There was no significant 
difference between the two groups. Therefore, a prediction 
of the cases where treatment is able to continue is difficult to 
conceive. Moreover, in a comparison between cases where 
adverse reactions appeared and cases where adverse reac-
tions did not appear, cases where adverse reactions did not 
appear were significantly younger. This may be because the 
administering techniques of elderly people are not as good: 
they may administer too many drops at once, and there are 
possibilities that they are dropping eye drops onto their 
  eyelids. Young people’s adherence to self-administration of 
the treatment may be poor due to forgetfulness.
In previous studies, eyelash growth was reported in 25.6% 
of subjects in a 3-month trial,5 2.9%6 and 31.2%2 in 12-week 
trials, 48.1% in a 24-week trial,6 10.5% in a 6-month trial,4 
and 42.8% in a 180-day trial.8 Although the administration 
periods and evaluation methods differed, the incidence of eye-
lash growth (46.2%) and eyelash bristle (53.8%) in this study 
was almost equivalent to that in other studies. The incidence 
of increased eyelid pigmentation was reported as 2.9%6 and 
10.4%2 in 12-week trials, 25.9%7 in a 24-week trial, 17.8%8 
in a 180-day trial, and 5.8%9 in a 12-month trial. Although 
the administration periods and evaluation methods differed 
in each of these studies, the incidence of increased eyelid 
pigmentation (7.9%) in the present study was mostly com-
parable with these results. Iris pigmentation in 3-month trials 
was reported as 0%3 and 0.4%,5 in a 6-month trial, 0.8%,4 
0%
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44.2 55.8
67.3 32.7
50.0 50.0
** **
46.2 53.8
Appeared Did not appear
Iris pigmentation
Eyelid pigmentation
Increase of vellus hair
of the lid
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Eyelash growth
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Figure 3 Subjective evaluation.
Note: **P , 0.0001 (chi-square test).
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Figure 4 Verification of objective and subjective evaluations. 
Note: **P , 0.0001(chi-square test).
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
114
Inoue et alClinical Ophthalmology 2012:6
and in a 12-week trial, ,5%.2 In this study we   evaluated iris 
pigmentation objectively as 50.0%, which might be more 
frequent than that in the previous studies.2–5 On the other 
hand, iris pigmentation induced by latanoprost treatment 
evaluated objectively has been reported as 16.3%, 34.2%, 
49.2%, 58.2%, and 58.2% at 6, 9, 9, 12, and 15 months after 
the start of latanoprost treatment.10 Frequency rates rose as 
progression occurred. In this study, we evaluated the adverse 
reactions of bimatoprost at only 6 months after treatment. 
A longer-term safety examination will be needed.
In previous evaluations, 0.0%,7 0.9%,5 1.5%,6 3.3%,3 
4.2%,2 4.5%,4 and 9.7%8 of patients discontinued bimatoprost 
because of adverse reactions. Reasons for discontinuing 
treatment included conjunctival hyperemia, ocular burning 
sensation, blurry visual acuity, photophobia,3 eyelid pigmen-
tation,2 instability dizziness,2 eyelid erythema and conjuncti-
val injection,2 ocular hyperemia,6 conjunctival hyperemia,4,5 
allergic skin reaction,5 blepharoptosis,5 eye pruritus,4 and 
ocular allergy.8 In this study, 14 patients (20%) discontinued 
bimatoprost treatment because of adverse reactions. Japanese 
patients might have a greater proclivity for adverse reactions 
to bimatoprost treatment. However, incidence of adverse 
reactions such as hyperemia, eyelid pigmentation, eyelash 
bristle, eye aching, headache, and foggy eyesight was not 
significantly different from previously reported incidences 
in other populations.2–7
A control group was not set up in this study. We have 
investigated the frequency of adverse reactions around the 
eyes caused by other prostaglandin analogs such as latano-
prost,11 travoprost,12 and tafluprost13 in our hospital using 
the same methods as this study (Figure 5). We took pictures 
before administration and after administration of prostaglan-
din analogs. There have been no reports performed in the 
same way as our reports.11–13 Therefore, we compared our 
results to those reports.
Inoue et al enrolled 101 patients for treatment with 
  latanoprost for 6 months.11 Eyelash growth appeared in 
50.5%, eyelash bristle in 28.7%, increase in vellus hair of the 
lid in 37.6%, eyelid pigmentation in 5.9%, and iris pigmenta-
tion in 31.7% of patients. Shiokawa et al treated 58 patients 
with travoprost for 6 months.12 Eyelash growth appeared 
in 34.5%, eyelash bristle in 17.2%, increase in vellus hair 
of the lid in 58.6%, eyelid pigmentation in 3.5%, and iris 
pigmentation in 37.9% of patients. Masumoto et al treated 
58 patients with tafluprost for 6 months.13 Eyelash growth 
appeared in 46.6%, eyelash bristle in 41.4%, increase of vel-
lus hair in the lid in 27.6%, eyelid pigmentation in 25.9%, 
and iris pigmentation in 34.5% of patients. Eyelash bristle 
under treatment with tafluprost and bimatoprost, increase in 
vellus hair of the lid under travoprost treatment, and eyelid 
pigmentation under tafluprost treatment were more frequently 
noted than with treatment using other prostaglandin analogs 
(P , 0.01; Chi-square test). The reasons underlying these 
disparities are unknown.
To understand patients’ acceptance of adverse events, 
a self-assessment questionnaire was employed. Even though 
the results of the comparison between objective and subjec-
tive assessments corresponded in the range of 48.1%–65.4%, 
the differences in results between objective and subjective 
assessments were markedly different for eyelid and iris 
pigmentation. This may be a result of informing the patients 
about possible eyelid pigmentation before starting the eye 
drops, thereby increasing patient consciousness of this poten-
tial reaction. To identify iris pigmentation, careful observa-
tion is required while standing in front of a mirror. Even if 
iris pigmentation occurs, it does not result in any visual or 
esthetical detriment. Therefore, it is often not noted. Two 
patients discontinued treatment due to eyelid pigmentation 
and eyelash bristle but we could not evaluate their subjective 
assessments. Sufficient explanation of adverse reactions is 
necessary prior to treatment. This may affect the number of 
patients who continue with treatment.
We observed three cases of discontinuation of treatment 
due to deepening of the upper eyelid sulcus. Because few 
studies have described this adverse reaction, its objective 
and subjective assessments were not examined in this study. 
However, recent studies have reported deepening of the 
upper eyelid sulcus following treatment with bimatoprost, 
  travoprost, and latanoprost.14–20 In the future, careful observa-
tion of deepening of the upper eyelid is recommended.
In conclusion, eyelash bristle, iris pigmentation, eyelash 
growth, increase in vellus hair of the lid, and eyelid pigmenta-
tion were noted, in order of frequency, when prospectively 
0.0
Bimatoprost (n = 52) this study Tafluprost (n = 58)L atanoprost (n = 101) Travoprost (n = 58) (%)
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*
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Figure 5 Comparison of adverse reactions among other prostaglandin analogs.11–13
Note: *P , 0.05.
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investigating adverse reactions to bimatoprost. Most patients 
were conscious of these adverse reactions. Sufficient explana-
tion and careful observation of potential adverse reactions 
are necessary when prescribing bimatoprost.
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